NCT03266692View on ClinicalTrials.gov

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Interventions
BIOLOGICAL

ACTR087

Autologous T cell product

BIOLOGICAL

SEA-BCMA

B-cell maturation antigen (BCMA)-directed antibody

Trial Locations (7)

32224

Mayo Clinic, Jacksonville

43210

Ohio State University Wexner Medical Center, Columbus

46327

Indiana Blood and Marrow Transplantation, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

75246

Baylor Scott & White, Dallas

85054

Mayo Clinic, Phoenix

02111

Tufts Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Cogent Biosciences, Inc.

INDUSTRY

NCT03266692 - Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter